(2,4,6-trimethylbenzenesulfonyl)carbamic acid tert-butyl ester | 56830-76-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2,4,6-trimethylbenzenesulfonyl)carbamic acid tert-butyl ester
• 英文别名: N-(tert-butoxycarbonyl)-N-mesitylenesulfonamide；N-(tert-butoxycarbonyl)mesitylenesulfonamide；N-(tert-butoxycarbonyl)-N-mesitylenesulfonylamide；O-tert-Butyl-N-mesitylsulfonylcarbamat；N-(Mesitylsulfonyl)carbamic acid tert-butyl ester；tert-butyl N-(2,4,6-trimethylphenyl)sulfonylcarbamate
• CAS: 56830-76-3
• 化学式: C₁₄H₂₁NO₄S
• 分子量: 299.391
• InChiKey: QNLCTIFJTPWCDT-UHFFFAOYSA-N

物化性质

• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2,4,6-trimethylbenzenesulfonyl)carbamic acid tert-butyl ester 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.5h， 生成 N-(but-2-yn-1-yl)-2,4,6-trimethylbenzenesulfonamide
  参考文献：
  名称：

  手性抗衡策略对映选择性IrI催化1,6-Enynes的碳环化。

  摘要：

  通过Ir I催化的1,6-烯炔的碳环化反应合成了对映体富集的双环[4.1.0]庚-2-烯。没有使用手性配体，CO和PPh 3是与铱结合的唯一配体。取而代之的是，立体化学信息位于催化剂的抗衡离子上，该催化剂是由Vaska络合物（反式[[IrCl（CO）（PPh 3）2 ]））与手性磷酸银反应而原位生成的。当使用这种催化混合物时，得到高达93％的对映体过量。31 P NMR和IR光谱表明，反式-[Ir（CO）（PPh 3）2 ] +的形成部分通过氯提取而发生。此外，密度泛函理论的计算支持该阳离子部分促进的6-内切-dig环化。手性磷酸根阴离子（O  P *）控制通过形成与金属中心的松散的离子对的对映选择性，并建立一个C  H⋅⋅⋅O 与基板P *氢键。这是非对称抗衡离子导向的过渡金属催化的罕见例子，代表了这种策略在CC键形成反应中的首次应用。

  DOI：

  10.1002/chem.201102723
• 作为产物：
  描述：

  2,4,6-二甲基苯磺酰胺 以 various solvent(s) 为溶剂， 反应 33.0h， 生成 (2,4,6-trimethylbenzenesulfonyl)carbamic acid tert-butyl ester
  参考文献：
  名称：

  Antiproliferative Properties of Polyamine Analogs: A Structure-Activity Study

  摘要：

  A basis set of polyamine analogues was designed and synthesized. These compounds were used to initiate a systematic investigation of the role of chain length, terminal nitrogen alkyl group size, and symmetry of the methylene backbone in the antineoplastic properties of polyamine analogues. New synthetic methods predicated on our earlier polyamine fragment synthesis are described for accessing the tetraamines of interest. An unsymmetrically substituted diamine reagent, N-(tert-butoxycarbonyl)-N,N'-bis(mesitylene sulfonyl)-1,4- di-aminobutane, was developed for entry into unsymmetrical tetraamines. All of the tetraamines synthesized were first evaluated in a murine leukemia L1210 cell IC50 assay at 48 and 96 h. In an attempt to correlate this behavior with some aspect of polyamine metabolism, each compound was tested for its ability to compete with spermidine for the polyamine uptake apparatus, its impact on the polyamine biosynthetic enzymes ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC), and its effect on the polyamine-catabolizing enzyme spermidine/spermine N-1-acetyltransferase (SSAT) and on polyamine pools. While there was no obvious correlation between the 48 and 96 h IC50'S and the impact of the analogues on polyamine metabolism, there were other structure-activity relationships. Correlations were observed to exist between chain length and IC50'S and between terminal alkyl substituents and impact on K-i, ODC, and AdoMetDC. Also, preliminary studies suggest a relationship may exist between the 48 and 96 h IC50's activities and the analogue's chronic toxicity in vivo. Finally, when the overall length of the polyamine backbone was held constant, the symmetry of the methylene chains of the polyamine fragments was shown to be unimportant to the compound's activity.

  DOI：

  10.1021/jm00047a004

文献信息

• 取代的杂芳基化合物及其组合物和用途
  申请人：广东东阳光药业有限公司

  公开号：CN109776522B

  公开（公告）日：2020-12-29

  本发明公开了取代的杂芳基化合物及其组合物和它们的用途。所述化合物为式(I)所示的化合物或者式(I)所示化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或它的前药。本发明还提供了包含所述化合物的药物组合物，所述化合物和药物组合物可以调节蛋白激酶，尤其是Aurora激酶和JAK激酶的活性，用于预防、处理、治疗和减轻蛋白激酶，尤其是JAK激酶活性介导的疾病或紊乱。
• Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment
  申请人：——

  公开号：US20030100615A1

  公开（公告）日：2003-05-29

  Polyamines having the formula: 1 or a salt thereof with a pharmaceutically acceptable acid wherein: R 1 -R 6 may be the same or different and are alkyl, aryl, aryl alkyl, cycloalkyl, optionally having an alkyl chain interrupted by at least one etheric oxygen atom, or hydrogen; N 1 , N 2 , N 3 and N 4 are nitrogen atoms capable of protonation at physiological pH's; a and b may be the same or different and are integers from 1 to 4; A, B and C may be the same or different and are bridging groups which effectively maintain the distance between the nitrogen atoms such that the polyamines: (i) are capable of uptake by a target cell upon administration thereof to a human or non-human animal; and (ii) upon uptake by the target cell, competitively bind via an electrostatic interaction between the positively charged nitrogen atoms to substantially the same biological counter-anions as the intracellular natural polyamines in the target cell; the polyamines, upon binding to the biological counter-anion in the cell, function in a manner biologically different than the intracellular polyamines, the polyamines not occurring in nature; as well as pharmaceutical compositions embodying the polyamines and methods of treating patients requiring anti-neoplastic therapy.

  聚胺具有以下化学式：1或其与药用可接受酸盐，其中：R1-R6可能相同或不同，为烷基、芳基、芳基烷基、环烷基，或可由至少一个醚氧原子中断的烷基链组成，或氢；N1、N2、N3和N4是氮原子，在生理pH下能够质子化；a和b可能相同或不同，为1至4的整数；A、B和C可能相同或不同，是有效维持氮原子之间距离的桥联基团，使得聚胺：(i)能够在给予人类或非人类动物后被靶细胞吸收；以及(ii)在被靶细胞吸收后，通过正电荷氮原子之间的静电相互作用与靶细胞内的天然聚胺基本相同地与生物学反离子结合；这些聚胺在细胞内与生物反离子结合后，以生物学上与细胞内聚胺不同的方式发挥作用，这些聚胺在自然界中不存在；以及包含聚胺的药物组合物和治疗需要抗肿瘤治疗的患者的方法。
• A Selective Rh^I -Catalyzed Substrate-Controlled C−C Bond Activation of Benzyl Sulfonamide/Alcohol-Tethered Alkylidenecyclopropanes
  作者：Kai Chen、Jia-Xin Liu、Xiang-Ying Tang、Min Shi

  DOI：10.1002/chem.201602366

  日期：2016.8.8

  Benzyl sulfonamide/alcohol‐tethered alkylidenecyclopropanes undergo a rhodium‐catalyzed and substrate‐controlled selective C−C bond activation, producing three types of common organic structural units: benzo[c]azepine/oxepines, dihydronaphthalen‐1‐amines, and conjugated dienes. Epoxidation and aromatization of these products to construct two useful compounds have also been achieved.

  苄基磺酰胺/醇系烷基亚烷基环丙烷经过铑催化和底物控制的选择性C-C键活化，产生三种常见的有机结构单元：苯并[c]氮杂/氧杂品，二氢萘-1-胺和共轭二烯。这些产物的环氧化和芳构化以构建两种有用的化合物也已经实现。
• [EN] NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES<br/>[FR] NOUVEAUX CONJUGUES D'ANALOGUE DE POLYAMINE ET CONJUGUES DE QUINONE, UTILISES POUR LE TRAITEMENT DE CANCERS ET DE MALADIES DE LA PROSTATE
  申请人：SLIL BIOMEDICAL CORP

  公开号：WO2000066175A2

  公开（公告）日：2000-11-09

  Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of prostate diseases are also provided.

  提供一种肽共轭物，其中将细胞毒性和细胞增殖抑制剂，如多胺类似物或萘醌类化合物，与多肽共轭，该多肽可以被酶如前列腺特异性抗原（PSA）和半胱氨酸蛋白酶B识别和剪切，以及包含这些共轭物的组合物。还提供了使用这些共轭物治疗前列腺疾病的方法。
• Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
  申请人：SLIL Biomedical Corporation

  公开号：US20040006049A1

  公开（公告）日：2004-01-08

  Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of prostate diseases are also provided.

  本发明提供了肽共轭物，其中将细胞毒性和细胞增殖抑制剂，如多胺类似物或萘醌类化合物，与被酶如前列腺特异性抗原（PSA）和半胱氨酸蛋白酶B识别和切割的多肽共轭。同时提供了包含这些共轭物的组合物。本发明还提供了使用这些共轭物治疗前列腺疾病的方法。